Morgan Stanley is an individual stock rather than an ETF, so the central target draws from specific analyst forecasts. I examined about 14 recent attributed targets issued after the third-quarter 2026 earnings release, with figures spanning roughly $190 to $262. Their arithmetic mean comes in near $218, which rounds to the $220 central target referenced here.
Opinions vary across the group. On the bullish side, Jefferies sets a $262 target and UBS a $240 target, while Keefe Bruyette maintains an Outperform rating with a $230 objective and highlighted the post-earnings decline as a “very attractive entry point,” pointing to recurring-revenue exposure and the firm’s ability to benefit from AI-driven wealth creation. In the middle range sit Bank of America at $220, BMO Capital at $210, and Evercore ISI at $205. More cautious voices include Wells Fargo at $217 (Equal Weight) and RBC Capital at $195. Wells Fargo’s Mike Mayo characterized the quarter as “very good but not great” and lowered forward estimates amid caution on capital markets.
The most recent verified closing price for Morgan Stanley (MS) is near $181.44. Closing the gap to the average analyst price target of $220 would imply upside of roughly 21%, a sizable move. The stock has traded within a 52-week range of about $152.80 to $232.25 and experienced a sharp drop from its highs before finding some stability, which explains why several analysts now see the current level as a more favorable risk-reward entry point.
On the fundamentals, the company posted third-quarter EPS of $3.03, roughly $0.10 above consensus estimates, alongside revenue of about $20.34 billion. Wealth Management delivered record revenue, pre-tax income, and net new assets that rose 11%, while Institutional Securities revenue climbed approximately 18% with equities revenue advancing about 41%. Return on tangible common equity reached 22.6%, marking the fifth straight quarter above 20%. A path to $220 would likely depend on continued wealth-management inflows, steady trading activity, and stabilization of the valuation multiple from its current level near 14x trailing P/E. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
The recent sharp decline from above $230 into the low $180s left a gap that now serves as overhead supply. The $180–$185 zone has acted as near-term support, while the $190–$195 area and the psychologically important $200 level mark the first resistance points on any recovery. A sustained advance toward the $220 target would need to reclaim the $210–$215 range, which lies just below the calculated mean and coincides with several recent target reductions.
Analyst price targets typically reflect a roughly 12-month horizon, though individual firms vary. Investors should monitor quarterly earnings and guidance, with particular attention to wealth-management net new assets, Institutional Securities revenue, and return on tangible common equity; additional analyst target revisions; interest-rate decisions; and the pace of M&A and capital-raising activity that directly influences the firm’s cyclical earnings.
From what I see, AI Daily Buy/Sell Signals from Tickeron can provide an additional layer of insight by continuously scanning thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical behavior and market conditions. For a name like MS, these signals help identify shifting trends and monitor positions more efficiently than manual review alone.
Can Morgan Stanley stock reach $220? The $220 central target, built from the average of about 14 verified analyst price targets that range from roughly $190 to $262, would require a substantial move of about 21% from the latest price near $181.44. The bull case rests on record wealth-management results, strong trading momentum, and a valuation reset after a steep correction. The bear case centers on cyclical capital-markets risks and the downward estimate revisions already made by several firms. With targets spread across a $70 range, even professional analysts hold differing views, and no outcome is assured.
I frequently turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one. The platform applies artificial intelligence to monitor market conditions and technical patterns across thousands of securities, helping surface timely signals that complement traditional research and support more systematic decision-making in my own workflow.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for MS moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 16 of the 20 cases the stock moved higher. This puts the odds of a move higher at 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MS as a result. In 55 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for MS just turned positive on October 21, 2026. Looking at past instances where MS's MACD turned positive, the stock continued to rise in 27 of 42 cases over the following month. The odds of a continued upward trend are 64%.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where MS advanced for three days, in 230 of 351 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 64 cases where MS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
MS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 5 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. MS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.674) is normal, around the industry mean (3.120). P/E Ratio (14.515) is within average values for comparable stocks, (6.734). Projected Growth (PEG Ratio) (1.702) is also within normal values, averaging (0.809). Dividend Yield (0.025) settles around the average of (8.976) among similar stocks. P/S Ratio (4.380) is also within normal values, averaging (16.899).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of diversified financial services including brokerage, investment management and venture capital services
Industry InvestmentBanksBrokers